AbbVie inc. (ABBV) said Monday that it has inititated a Phase 3 clinical study called SONAR to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.
SONAR is a large, multinational, double-blind, placebo-controlled clinical study that is expected to enroll more than 4,000 patients with diabetic nephropathy. The study will evaluate atrasentan's impact on renal outcomes, such as the onset of end-stage renal disease, as defined by need for chronic dialysis, transplant or death due to renal failure progression.
The initiation of the Phase 3 study follows results from Phase 2b studies, which were presented Friday during a late breaking clinical trials scientific session at the 2013 European Renal Association-European Dialysis and Transplant Association Congress in Istanbul, Turkey.
Diabetic nephropathy, or diabetic kidney disease, is a common complication of diabetes and the leading cause of chronic kidney disease in the developed world. In the US, about 40% of patients with diabetes develop diabetic nephropathy.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.